For example, combining a histone deacetylase inhibitor with TRAIL can improve the resistance of Hepatoblastoma cell lines to TRAIL, which is friendly to normal cells (Dzieran et al., 2008). This evidence concerns the gene TNFSF10 and hepatoblastoma.